Atlanta Journal-Constitution Profiles Three Upcoming Clinical Trials of Tenofovir for HIV Prevention
February 6, 2004
The Atlanta Journal-Constitution on Thursday profiled three upcoming clinical trials of the antiretroviral drug Viread, which is known generically as tenofovir, to determine whether the drug can prevent HIV infection (Wahlberg, Atlanta Journal-Constitution, 2/5). NIH, CDC and the Bill & Melinda Gates Foundation are funding three separate human studies of Viread, which is manufactured by Gilead Sciences and is FDA-approved for use as a treatment for HIV infection. The drug has been shown to boost immune response and lower viral levels in the bloodstreams of patients who are resistant to other antiretrovirals. The Gates Foundation has awarded a $6.5 million grant to Family Health International to conduct a randomized, placebo-controlled clinical trial to evaluate whether Viread is effective at reducing the risk of HIV infection. The trial will include 2,000 volunteers in Cambodia, Ghana, Cameroon, Nigeria and Malawi. All of the study participants will receive safe sex counseling and condoms even though their use may make it more difficult to prove whether the drug works to prevent HIV infection. NIH has awarded a $2.1 million grant to University of California-San Francisco researchers to test Viread in 960 Cambodian women, most of whom are sex workers. In addition, CDC has granted $3.5 million to fund a third study examining Viread's safety as a preventive among sexually active men who have sex with men in San Francisco and Atlanta (Kaiser Daily HIV/AIDS Report, 12/4/03).
Wealthy Nations Must Stop "Decade of Financial Abstinence," Increase International AIDS Spending, U.N. Envoy Lewis Says
This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily HIV/AIDS Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.